Clinical Trials Browser

Lymphoma, B-Cell × obinutuzumab × 30 days × Clear all

NCT06634589 2026-06-03

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Phase 1/2 Recruiting

Neoplasms, Recurrence, Lymphoma, B-Cell